Pfizer Inc. has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million.

This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population.

The acquisitions follow Pfizer’s purchase last year of Baxter International’s meningococcal disease vaccine NeisVac-C, as well as approval in the U.S. of its drug Trumenba to protect against erogroup B meningococcal disease in individuals 10 through 25 years of age.